Supporting Information

Design of Bifunctional Dendritic 5-Aminolevulinic Acid and Hydroxypyridinone Conjugates for Photodynamic Therapy

Tao Zhou,*,h,a Sinan Battah,§,h,d Francesca Mazzacua,c Robert C. Hider,c Paul Dobbin,b Alexander J. MacRobertd

a. School of Food Science and Biotechnology, Zhejiang Gongshang University, Hangzhou, Zhejiang 310035, P. R. China.
b. School of Biological Sciences, University of Essex, Wivenhoe Park CO4 3SQ
c. Division of Pharmaceutical Sciences, King’s College London, 150 Stamford Street, London SE1 9NH
d. Division of Surgery and Interventional Science, University College London, Charles Bell House, 43-45 Foley St, London W1W 7TS

Corresponding author.

*(T.Z.) E-mail: taozhou@zjgsu.edu.cn
Figure S1. PpIX production in MCF-7 and MCF-7R cells treated with 300 µM of ALA or 60 µM ALA-HPO dendrimer 30a. Cells were exposed to the compounds for times up to 60 min and then washed to remove the excess compounds. Fluorescence readings were recorded at two later time-points to compare porphyrin levels. (A) fluorescence readings taken after 4 h from the time point at which cells were first exposed to the compound; (B) fluorescence readings were taken after 24 h.
Figure S2: Dark toxicity after incubation with (100 µM) of ALA and dendritic ALA-HPO without irradiation assessed by MTT assay in KB, MCF-7, and MCF-7R for 24 h.